Azenta Inc Stock Price, News & Analysis

Azenta, Inc. (Nasdaq: AZTA) announced its participation in the 22nd Annual Needham Virtual Healthcare Conference scheduled for April 18, 2023, with a presentation starting at 9:30 am ET. Investors can access the live webcast via Azenta's investor relations website, and a replay will be available after the event.

Azenta is a leading provider of life sciences solutions, focusing on enhancing drug development and clinical research. The company offers a comprehensive range of cold-chain sample management solutions and genomic services for pharmaceutical, biotech, and healthcare institutions globally. Headquartered in Burlington, MA, Azenta operates in North America, Europe, and Asia. For further details, visit www.azenta.com.

Azenta, Inc. (Nasdaq: AZTA) will participate in the Virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023, with a presentation starting at 4:30 pm ET. Investors can access the live webcast on the Azenta investor relations website and a replay will be available after the event. Azenta is a global leader in life sciences solutions, offering cold-chain sample management and genomic services for drug development and clinical research. Headquartered in Burlington, MA, the company operates across North America, Europe, and Asia.

Azenta, Inc. (Nasdaq: AZTA) announced its participation in two investor conferences in March 2023. The first event is the Cowen 43rd Annual Health Care Conference in Boston, MA, on March 7th, featuring a presentation at 12:50 pm ET. The second is the Barclays Global Healthcare Conference in Miami, FL, on March 15th, with a presentation starting at 3:35 pm ET. Investors can access the live webcasts via the Azenta investor relations website, with replays available thereafter. Azenta provides life sciences solutions, focusing on cold-chain sample management and genomic services for global healthcare institutions.

Azenta (NASDAQ: AZTA) has launched the Cryo Store Pico™, an automated cryogenic storage system aimed at high-value biological samples across various stages of life sciences. The Pico enhances sample integrity and regulatory compliance, offering features specifically tailored for cell and gene therapy developers. It facilitates controlled access and traceability while maintaining a compact design for clinical use. The product is now available for order and will be showcased at the SLAS 2023 International Conference in San Diego, CA. Azenta aims to speed up breakthroughs in life sciences with its innovative cryogenic solutions.

Ansa Biotechnologies has appointed Dr. Matthew F. McManus as Independent Director and Chairperson of its Board of Directors. Dr. McManus, who has extensive experience in the life sciences industry, was previously the EVP and COO at Azenta (NASDAQ:AZTA). He has held leadership roles at Bio-Techne and PrimeraDx, leading key transformations in the molecular diagnostics sector. His expertise is expected to enhance Ansa's growth, particularly in commercializing its proprietary DNA synthesis technology, which promises advancements in medicine, agriculture, and industrial biology.

Azenta, Inc. (Nasdaq: AZTA) will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15-16, 2023. Interested participants should contact their BTIG representative to attend. Azenta is recognized globally for providing life sciences solutions, facilitating faster market delivery of breakthroughs and therapies. Their comprehensive offerings include cold-chain sample management and genomic services, primarily serving pharmaceutical, biotech, academic, and healthcare institutions worldwide. The company is based in Burlington, MA, with operations spanning North America, Europe, and Asia.

Azenta, Inc. (Nasdaq: AZTA) reported Q1 2023 revenue of $178 million, a 28% year-over-year increase, driven by an 80% surge in Life Sciences Products revenue, thanks to the acquisition of B Medical. Organic revenue growth, excluding COVID impacts, stood at 7%.

Despite these gains, the company recorded a diluted EPS loss of ($0.15) and an operating loss of $28 million. Management aims to streamline operations for a projected 2% margin improvement in the second half of FY23. Guidance for Q2 2023 estimates revenue between $156 million and $171 million with a non-GAAP EPS forecast of (0.04) to 0.04.

Azenta, Inc. (Nasdaq: AZTA) is set to announce its fiscal first quarter 2023 earnings on February 8, 2023, after market close. The earnings period concluded on December 31, 2022. Following the announcement, the company will hold a conference call at 4:30 p.m. ET to discuss the financial results. Analysts and investors can dial in or access the live webcast via the Azenta website. Azenta, headquartered in Burlington, MA, provides life sciences solutions, including cold-chain sample management and genomic services, aiding pharmaceutical, biotech, and healthcare sectors globally.